Market Research Report
Biosimilars Market Access in Psoriasis
|Published by||Datamonitor Healthcare||Product code||498964|
|Published||Content info||24 Pages
Delivery time: 1-2 business days
|Biosimilars Market Access in Psoriasis|
|Published: March 23, 2017||Content info: 24 Pages||
Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriasis market; however, these market leaders face patent expirations and consequent biosimilar launches. Payers are eager to leverage these changes in the competitive landscape and enact pro-biosimilar access measures, resulting in downward pricing pressures and/or continuing market erosion for first-generation TNF-alpha inhibitors. This rate of erosion may initially be gradual, as neither physicians nor payers are likely to advocate patient switching.